Cargando…
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
BACKGROUND: Cystic fibrosis (CF) is an inherited, rare autosomal recessive disease that results in chronically debilitating morbidities and high premature mortality. We evaluated how ivacaftor treatment affected CF symptoms, functioning, and well-being, as measured by the Cystic Fibrosis Questionnai...
Autores principales: | Quittner, Alexandra, Suthoff, Ellison, Rendas-Baum, Regina, Bayliss, Martha S., Sermet-Gaudelus, Isabelle, Castiglione, Brenda, Vera-Llonch, Montserrat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702321/ https://www.ncbi.nlm.nih.gov/pubmed/26135562 http://dx.doi.org/10.1186/s12955-015-0293-6 |
Ejemplares similares
-
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study
por: Bell, Scott C., et al.
Publicado: (2019) -
Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
por: Bernarde, Cédric, et al.
Publicado: (2015) -
Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013) -
Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation
por: Wood, Michelle E, et al.
Publicado: (2013) -
Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation
por: Zeybel, Gemma L., et al.
Publicado: (2017)